Lisata Therapeutics (NASDAQ:LSTA) Shares Down 0.9% – What’s Next?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was down 0.9% during trading on Thursday . The company traded as low as $3.30 and last traded at $3.33. 13,041 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 76,951 shares. The stock had previously closed at $3.36.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Stock Down 0.9%

The company has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.66. The stock has a market capitalization of $30.34 million, a price-to-earnings ratio of -1.79 and a beta of 0.79.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter. Equities analysts anticipate that Lisata Therapeutics, Inc. will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Lisata Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Deltec Asset Management LLC acquired a new position in shares of Lisata Therapeutics during the first quarter worth about $451,000. Rangeley Capital LLC purchased a new position in Lisata Therapeutics during the first quarter worth about $376,000. Ground Swell Capital LLC lifted its position in Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after purchasing an additional 15,213 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Lisata Therapeutics in the third quarter valued at about $37,000. Finally, Cerity Partners LLC acquired a new stake in Lisata Therapeutics in the second quarter valued at about $32,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.